 |
13 Diseases |  |
3 Trials |
|
3 Trials |  |
119 News |  |
| «123 |
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 25, 2019
P1, N=10, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting | Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Feb 2019 --> Feb 2020
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment change, Trial withdrawal, PD(L)-1 Biomarker: Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a (clinicaltrials.gov) - Mar 11, 2019
P1b/2a, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting | Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Feb 2019 --> Feb 2020 N=21 --> 0 | Not yet recruiting --> Withdrawn
- || Keytruda (pembrolizumab) / Merck (MSD), letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open, Metastases: Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab (clinicaltrials.gov) - Feb 11, 2019
P1b/2a, N=44, Recruiting, Sponsor: GlaxoSmithKline
N=21 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jan 4, 2019
P1/2, N=9, Active, not recruiting, Sponsor: Adaptimmune
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2018 --> Jun 2017
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Phase classification, Trial completion date, Trial initiation date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 16, 2018
P1, N=10, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2018 --> Jun 2017 Phase classification: P1/2 --> P1 | Trial completion date: Jan 2019 --> Sep 2019 | Initiation date: Nov 2015 --> Feb 2016
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Phase classification, Enrollment change, Trial primary completion date, Metastases: ADP-0011-007: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (clinicaltrials.gov) - Oct 16, 2018
P2, N=10, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P1/2 --> P1 | Trial completion date: Jan 2019 --> Sep 2019 | Initiation date: Nov 2015 --> Feb 2016 Phase classification: P1/2 --> P2 | N=15 --> 10 | Trial primary completion date: May 2018 --> Jun 2020
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Phase classification, Trial completion date, PD(L)-1 Biomarker: KEYNOTE-487: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma (clinicaltrials.gov) - Oct 4, 2018
P2, N=24, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P1/2 --> P2 | N=15 --> 10 | Trial primary completion date: May 2018 --> Jun 2020 Phase classification: P1 --> P2 | Trial completion date: Sep 2024 --> Apr 2021
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Oct 1, 2018
P1, N=10, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P1 --> P2 | Trial completion date: Sep 2024 --> Apr 2021 Phase classification: P1/2 --> P1 | N=65 --> 10 | Trial completion date: Mar 2028 --> May 2020 | Trial primary completion date: Oct 2018 --> May 2020
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment change, Trial completion date, Trial termination: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jul 24, 2018
P1/2, N=6, Terminated, Sponsor: Adaptimmune
Phase classification: P1/2 --> P1 | N=65 --> 10 | Trial completion date: Mar 2028 --> May 2020 | Trial primary completion date: Oct 2018 --> May 2020 N=10 --> 6 | Trial completion date: Apr 2031 --> Apr 2018 | Active, not recruiting --> Terminated; Sponsor Decision
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Apr 11, 2018
P1/2, N=65, Recruiting, Sponsor: Adaptimmune
N=10 --> 6 | Trial completion date: Apr 2031 --> Apr 2018 | Active, not recruiting --> Terminated; Sponsor Decision Trial primary completion date: Oct 2017 --> Oct 2018
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 11, 2018
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jan 11, 2018
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Aug 7, 2017
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2017 --> Jul 2018
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jun 29, 2017
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Apr 2017 --> Dec 2017
- |||||| letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open, PD(L)-1 Biomarker: KEYNOTE-487: Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2017
P, N=20, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Apr 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 6, 2017
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2017 --> Jan 2019
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Jan 26, 2017
P1/2, N=65, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Nov 2017 --> Jan 2019 Trial primary completion date: Mar 2017 --> Oct 2017
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial, Metastases: ADP-0011-007: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma (clinicaltrials.gov) - Dec 14, 2016
P1/2, N=15, Recruiting, Sponsor: Adaptimmune
- | letetresgene autoleucel (GSK3377794) / Adaptimmune
Phase classification: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Jul 1, 2016
P1/2, N=60, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Mar 2017 --> Oct 2017 Phase classification: P1 --> P1/2
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jun 11, 2016
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Phase classification: P1 --> P1/2 Recruiting --> Active, not recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jan 28, 2016
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jan 28, 2016
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 21, 2016
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Jul 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- || letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment change, Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Dec 12, 2015
P1, N=60, Recruiting, Sponsor: Adaptimmune
Not yet recruiting --> Recruiting N=10 --> 60 | Trial primary completion date: Mar 2016 --> Mar 2017
- letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial, Metastases: Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Oct 28, 2015
P1/2, N=10, Not yet recruiting, Sponsor: Adaptimmune
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Nov 3, 2014
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
N=10 --> 60 | Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Apr 2015 --> Apr 2016
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Nov 3, 2014
P1/2, N=6, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Jul 2014 --> Jul 2016
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: ADP 04511: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1? (clinicaltrials.gov) - Nov 3, 2014
P1, N=10, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Jul 2014 --> Jul 2016 Trial primary completion date: Mar 2014 --> Mar 2016
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Sep 23, 2013
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
Trial primary completion date: Mar 2014 --> Mar 2016 Not yet recruiting --> Recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jul 2, 2013
P1/2, N=10, Recruiting, Sponsor: Adaptimmune
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial initiation date: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jun 26, 2013
P1/2, N=6, Recruiting, Sponsor: Adaptimmune
Not yet recruiting --> Recruiting Initiation date: Feb 2012 --> Jun 2013
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment open: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jun 20, 2013
P1/2, N=6, Recruiting, Sponsor: Adaptimmune
Initiation date: Feb 2012 --> Jun 2013 Withdrawn --> Recruiting
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment change: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Jan 30, 2013
P1/2, N=6, Recruiting, Sponsor: Adaptimmune
Withdrawn --> Recruiting N=12 --> 6
- letetresgene autoleucel (GSK3377794) / Adaptimmune
New P1/2 trial: CT Antigen TCR-redirected T Cells for Ovarian Cancer. (clinicaltrials.gov) - Mar 28, 2012
P1/2, N=6, Recruiting, Sponsor: Adaptimmune